We are live on
!
Find out more
EAM
Eventide Asset Management Portfolio holdings
AUM
$6.05B
1-Year Est. Return
76.64%
This Fund
S&P 500
This Quarter
Est. Return
+16.39%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$6.4B
AUM Growth
+$319M
(+5.3%)
Cap. Flow
-$190M
Cap. Flow
% of AUM
-2.98%
Top 10 Holdings %
Top 10 Hldgs %
23.07%
Holding
289
New
50
Increased
129
Reduced
80
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ionis Pharmaceuticals
IONS
|
+$43.3M |
| 2 |
Liberty Energy
LBRT
|
+$32.9M |
| 3 |
DexCom
DXCM
|
+$30.7M |
| 4 |
Apogee Therapeutics
APGE
|
+$27.5M |
| 5 |
Monolithic Power Systems
MPWR
|
+$26.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$95.2M |
| 2 |
VRNA
Verona Pharma
VRNA
|
+$72.7M |
| 3 |
Guardant Health
GH
|
+$72.5M |
| 4 |
Celcuity
CELC
|
+$63.7M |
| 5 |
Evolent Health
EVH
|
+$53.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 42.37% |
| 2 | Industrials | 17.69% |
| 3 | Technology | 15.85% |
| 4 | Consumer Discretionary | 6.94% |
| 5 | Utilities | 5% |
Similar funds
HPG
EMPI
RCG
JWBC
AAM
AA
CM
CIS
Eventide Asset Management's Q4 2025 Portfolio in Review
As of Q4 2025, Eventide Asset Management held 289 positions worth $6.4B, up 5.3% from $6.08B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Eventide Asset Management's Q4 2025 filing shows 50 new, 129 increased, 80 reduced and 21 closed positions. Its largest new stake was Ionis Pharmaceuticals: 575,000 shares worth $45.5M. The largest sale was Insmed, an estimated $95.2M.
By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 38% a quarter earlier, followed by Industrials and Technology.
- Eventide Asset Management's largest Q4 2025 buy was Ionis Pharmaceuticals: 575,000 shares worth $45.5M.
- Eventide Asset Management added most to Monolithic Power Systems in Q4 2025, an estimated $26.1M increase.
- Eventide Asset Management's biggest Q4 2025 reduction was Insmed, cutting an estimated $95.2M.
- Eventide Asset Management fully exited Verona Pharma in Q4 2025, selling an estimated $72.7M.
- Eventide Asset Management's ten largest holdings make up 23% of its $6.4B portfolio in Q4 2025.
- Eventide Asset Management opened 50 new positions and closed 21 in Q4 2025.
- Eventide Asset Management's portfolio value rose 5.3% quarter-over-quarter to $6.4B.
Based on Eventide Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.